Responsible And Regulated E-Cigarette Manufacturing And Rigorous Industry Standards Are Vital To Creating A Long-Term Product Portfolio

COSTA MESA, CA / ACCESSWIRE / August 31, 2020 / Charlie's Holdings, Inc. (OTC PINK:CHUC) ("Charlie's" or the "Company"), an industry leader in both the premium, nicotine-only, e-cigarette space and the hemp-derived, CBD wellness space, is pleased to announce the filing of its initial Premarket Tobacco Application ("PMTA") submission with the Food and Drug Administration ("FDA"), as it remains committed to being a leader in responsible manufacturing and promoting the highest standards of regulatory compliance.

Today's submission marks the first of multiple applications that Charlie's Chalk Dust ("CCD") intends to take through FDA's approval process as it seeks to create a long-term, robust product portfolio.

"This is a day we've long awaited for in our industry," stated, Charlie's Holdings' Chief Operating Officer Ryan Stump. "After spending nearly $5 million over the past two years on our PMTA preparation and submission, we are extremely excited about the application we filed with the FDA. Today is a great achievement for our Company and will greatly benefit our customers, our partners, and our shareholders."

Mr. Stump, continued, "We strongly believe our commitment to maintaining the highest standards of regulatory compliance is a huge differentiating factor for our Company. We feel that a significant amount of our competitors will not have the resources, desire, and/or expertise to complete the extensive and costly PMTA process and that once complete, we will be able to benefit from being one of only a select group of companies responsibly operating in the flavored nicotine product space."

All manufacturers of any newly deemed tobacco products, including e-liquid derived from tobacco, must seek authorization approval to sell such products in the United States. In an effort to satisfy the FDA's requirements, CCD chose to partner with Blackbriar Regulatory Services ("BRS"), experts in the tobacco products regulatory space, to create the roadmap for its PMTA submissions. Mr. Stump, expressed, "It made perfect sense for us to partner with such a reputable company in BRS, having worked so closely over the years with their leadership team and FDA registered manufacturing facility."

The FDA PMTA guidance asked brands to gain a deep understanding of public perceptions of Electronic Nicotine Delivery Systems ("ENDS") products and the behavior of ENDS users. BRS developed a novel research program consisting of a suite of interrelated studies designed to approach FDA's questions from multiple angles. When combined, the results provide a comprehensive picture of perceptions and behaviors around CCD's products and ENDS in general.

As a further measure to demonstrate the quality of our application, we are excited to say that we are also performing human clinical trials on our products to help detect the biomarkers of exposure associated with smoking combustible cigarettes and determine the nicotine delivery efficiency of the product via pharmacokinetic studies. A large team of doctors, scientists, biostatisticians, and data analysts are conducting these time intensive clinical trials. We believe that this kind of study will significantly set our application apart from those that are relying solely on the literature-based approach to this critical "in human" assessment of product performance.

"Charlie's was clear with us about their long-term strategy when we first started working with them several years ago," said, Russ Rogers, Chief Executive Officer at Blackbriar Regulatory Services. "They emphasized the importance of BRS having its manufacturing facilities and quality system exceed all FDA standards and fully appreciate the benefits they get from manufacturing in an FDA registered medical products facility. When we started discussing PMTA strategy options with Charlie's, they specifically wanted an approach tailored around quantifying what makes them unique in a highly competitive market space. AVAIL Vapor's recent announcement on the status of their PMTA submission by BRS must give Charlie's great confidence in the PMTA strategy that they chose to invest in." On August 11, 2020 AVAIL Vapor announced their initial application had been moved to the substantive scientific review phase of FDA's approval process. This further distinguishes the roadmap BRS has put together as superior to the others that have and will be submitted to the FDA.

"We are thrilled to see that Charlie's has remained so strongly committed to the regulatory process," said, James Xu, Chairman of AVAIL Vapor. "And we couldn't be more excited to continue our long-term partnership and shared passions with them as we all move forward in this new highly regulated industry."

About AVAIL Vapor

Richmond, Virginia-based AVAIL Vapor is a premium retailer that offers a broad array of products online and in its 99 stores across 12 states. The company delivers on the promise of quality and transparency. Information on AVAIL products is available through retail stores and on the web at www.availvapor.com.

About Blackbriar Regulatory Services

Richmond, Virginia-based Blackbriar Regulatory Services specializes in helping small to mid-sized domestic and international companies navigate the United States regulatory landscape to bring their FDA-regulated products to market. BRS provides regulatory and analytical laboratory services, good manufacturing processes (GMP) and regulatory audits, as well as contract manufacturing and distribution for a range of markets regulated by the FDA. Information on BRS services can be found at www.bb-rs.com.

About Charlie's Holdings, Inc.

Charlie's Holdings, Inc. (OTC Pink: CHUC) is an industry leader in both the premium, nicotine-only, e-cigarette space and the hemp-derived, CBD wellness space through its subsidiary companies Charlie's Chalk Dust, LLC and Don Polly, LLC. Charlie's Chalk Dust produces high quality vapor products currently distributed in over 90 countries around the world. Charlie's Chalk Dust has developed an extensive portfolio of brand styles, flavor profiles and innovative product formats. Launched in June of 2019, Don Polly, LLC formulates innovative hemp-derived CBD wellness products. Don Polly's high-quality CBD products derive from single-strain-sourced hemp extract and high purity CBD isolate crystals.

For additional information, please visit our corporate website at: CharliesHoldings.com and our branded online websites: CharliesChalkDust.com and EnjoyPachamama.com.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company's overall business, existing and anticipated markets and expectations regarding future sales and expenses. Words such as "expect," "anticipate," "should," "believe," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "could," "intend," variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company's ability to successful increase sales and enter new markets; the Company's ability to manufacture and produce product for its customers; the Company's ability to formulate new products; the acceptance of existing and future products; the complexity, expense and time associated with compliance with government rules and regulations affecting nicotine and products containing cannabidiol; litigation risks from the use of the Company's products; risks of government regulations; the impact of competitive products; and the Company's ability to maintain and enhance its brand, as well as other risk factors included in the Company's most recent quarterly report on Form 10-K, Form 10-Q and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Investors Contact:

IR@charliesholdings.com
p949-418-4020

SOURCE: Charlie's Holdings, Inc.

ReleaseID: 603913

VANCOUVER, BC / ACCESSWIRE / August 31, 2020 / Silver Range Resources Ltd. (TSXV:SNG) ("Silver Range") is pleased to announce that it has signed a Definitive Agreement with Rush Gold Corp. ("Rush Gold") to allow Rush Gold to option the drill-ready Skylight Project ("Skylight") in Nevada.

Skylight is a low sulphidation epithermal prospect, located 60 kilometres northwest of Tonopah in the Royston Hills. Exploration work to date indicates that Skylight is a fully preserved, precious metal bearing epithermal system, the heart of which has never been drill tested.

Skylight is underlain by Oligocene ash-flow tuffs unconformably overlying Triassic Luning Formation carbonates and clastics. These rocks are cut by northwest-trending right lateral strike-slip faults and by subordinate north-striking steeply-dipping secondary normal faults splayed from the master faults. Skylight is centred on vent-proximal silica breccia and thinly laminated ponded silica indicating deposition at the very top of a hydrothermal cell in an epithermal outflow zone. The silica centres form several resistant hills extending approximately 800 m. Anomalous soil and rock geochemical responses in mercury, gold, silver and arsenic are associated with the silica. Silver Range conducted a three-dimensional induced polarization (3DIP) survey over a grid centred on the silica caps at Skylight. The survey defined a network of chargeability linears with a nexus centred beneath the region of the silica caps. Elevated gold, silver and arsenic values are directly associated with several of these linear chargeability anomalies. These linears are interpreted to be conduits feeding the hydrothermal system and may host high-grade vein-hosted precious metal mineralization.

Skylight drew no attention from early prospectors due to the lack of readily exposed gold or silver mineralization but was recognized as a significant target in the early 2000's by Rimfire Minerals Corporation and Newmont Mining. At the conclusion of their joint venture, Rimfire drilled 6 holes (1575 metres) on the flanks of the silica caps at Skylight in 2007. (Rimfire Minerals Corporation News Release – November 6, 2007). Intercepts were reported from three holes: 10.67 m @ 0.49 g/t Au; 3.05 m @ 1.766 g/t Au; and 3.05 m @ 0.608 g/t Au. This work was never followed up and the core of the system beneath the silica caps was never drill tested.

Transaction terms

Rush Gold can acquire a 100% interest in the Skylight Property over a three-year period by making cash payments totalling $320,000; completing an IPO by March 31, 2021; issuing 650,000 shares to Silver Range; and completing 3,000 metres of drilling. Silver Range will retain a 3% Net Smelter Return, 2/3 of which may be purchased by Rush Gold for $1,000,000 at any time prior to production. In addition, Silver Range will be entitled to receive a defined resource payment of US$4 per ounce of gold-equivalent Measured and Indicated Resources defined at Skylight to Canadian Institute of Petroleum Mining and Metallurgy standards for resource definition. If Rush Gold has not defined a resource to these standards on the property by the sixth anniversary of the Definitive Agreement, Silver Range shall be entitled to receive US$10,000 on the sixth and subsequent anniversaries until a resource is defined.

Silver Range is a precious metals prospect generator working in Nevada, Nunavut and the Northwest Territories. Silver Range has a portfolio of 23 active projects in Nevada. In total, the company has assembled a portfolio of 45 properties, 11 of which are currently optioned and being explored by partners. Silver Range is actively seeking joint venture partners to explore the high-grade precious metal targets in its portfolio.

Additional information on Silver Range's properties may be found on the company's website at www.silverrangeresources.com.

ON BEHALF OF SILVER RANGE RESOURCES LTD.

"Mike Power"

President, C.E.O. & Director

For further information concerning Silver Range or its exploration projects please contact:

Investor Inquiries

Richard Drechsler
Vice-President, Communications
Tel: (604) 687-2522
NA Toll-Free: (888) 688-2522
rdrechsler@silverrangeresources.com
http://www.silverrangeresources.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward looking statements based on assumptions and judgments of management regarding future events or results that may prove to be inaccurate as a result of exploration and other risk factors beyond its control, and actual results may differ materially from the expected results.

SOURCE: Silver Range Resources Ltd.

ReleaseID: 603870

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Todos Medical Ltd. (OTCQB:TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer's disease, today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 4:00 PM EST. Gerald Commissiong, President & CEO of Todos will be presenting to a live virtual audience.

For the real time presentation register here: https://ld500.ldmicro.com/. In addition, a replay will be available on Todos' website here.

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space." stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View Todos Medical's profile here: http://www.ldmicro.com/profile/TOMDF

Profiles powered by LD Micro – News Compliments of Accesswire

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB:TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain. In July 2020, Todos completed the acquired Breakthrough Diagnostics, Inc., the owner of the LymPro Test intellectual property, from Amarantus Bioscience Holdings, Inc. (OTC: AMBS).

Additionally, Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed strategic partnerships with Meridian Health, Moto-Para Foundation to deploy COVID-19 testing in the United States.

For more information, please visit https://www.todosmedical.com/.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Investor Contact:

Kim Sutton Golodetz
LHA Investor Relations
Senior Vice President
(212) 838-3777
kgolodetz@lhai.com

Corporate Contact:

Priyanka Misra
Todos Medical
(917) 882-3733
priyanka@todosmedical.com

SOURCE: Todos Medical via LD Micro

ReleaseID: 603859

The DA913X-A product family with fully integrated FETs boasts high efficiency and small footprints, requiring few external components

LONDON, UK / ACCESSWIRE / August 31, 2020 / Dialog Semiconductor plc (XETRA:DLG), a leading provider of battery management, AC/DC power conversion, Wi-Fi(R) and Bluetooth(R) low energy and Industrial ICs, today announces the DA913X-A product family, a new line of highly efficient, high-current, automotive-grade, step-down DC-DC (Buck) converters.

The highly integrated DA913X-A devices require fewer external components than competing solutions, enabling a low system BoM cost and a reduced solution footprint. The devices operate at efficiency levels above 90%, reducing the thermal design challenges for powering high-current rails in a wide range of automotive systems, including infotainment, navigation, telemetry, and Advanced Driver Assistance Systems (ADAS).

The DA913X-A family is comprised of three devices configured as single- or dual-output buck converters. The DA9130-A operates as a single-channel, dual-phase buck converter, delivering up to a 10 A output current. The DA9131-A integrates two single-phase buck converters, each delivering up to 5 A output current. The DA9132-A also integrates two single-phase buck converters, each delivering up to 3 A output current. All devices have an input voltage range of 2.5 V to 5.5 V and an output voltage range of 0.3 V to 1.9 V, making them suitable for a wide variety of low-voltage systems. Output voltages above 1.9V are supported with an external resistor divider.

"Dialog continues to introduce new PMIC solutions that meet the increasing power and thermal efficiency requirements of high-performance, in-cabin automotive electronics systems," said Tom Sandoval, Senior Vice President, GM Automotive Business Segment, Dialog Semiconductor. "Automotive system developers can rely on Dialog for the leading, cost-efficient, small-form factor, power solutions."

The DA913X-A products include several key features to meet the needs of today's complex automotive electronics systems:

Remote sensing guarantees the highest accuracy and supports multiple PCB routing scenarios without loss of performance.
Fully programmable soft start limits the in-rush current from the input to give a slope-controlled output voltage.
Dynamic voltage control (DVC) enables adaptive adjustment of the supply voltage dependent on the load. This increases efficiency when the downstream circuitry enters low power or idle mode, resulting in power savings.
Configurable GPIOs support a range of features including I2C, DVC and Power Good indicator.
Optimized BoM cost and footprint: Each output requires a very small inductor and capacitor.

The DA9130X-A devices are AEC-Q100 Grade 2 qualified and are available in a 3.3mm x 4.8mm a 24-pin FC-QFN wettable flank package. Industrial/commercial grade versions are also available.

For more information on this new product family, please visit pages for the DA9132, DA9131, DA9131-A, DA9130, DA9130-A and DA9132-A.

ENDS

NOTES:

Dialog, and the Dialog logo are trademarks of Dialog Semiconductor plc or its subsidiaries. All other product or service names are the property of their respective owners. (c) Copyright 2020 Dialog Semiconductor. All rights reserved.

Media Contact:
Mark Tyndall
SVP Corporate Development & Strategy
Dialog Semiconductor
Phone: +1 (408) 845 8520
mark.tyndall@diasemi.com
Web: www.dialog-semiconductor.com
Twitter: @DialogSemi

About Dialog Semiconductor

Dialog Semiconductor is a leading provider of standard and custom integrated circuits (ICs) that power the Internet of Things and Industry 4.0 applications. Dialog's proven expertise propels the next generation of today's devices by providing Battery Management, Bluetooth(R) low energy, Wi-Fi, Flash memory, and Configurable Mixed-signal ICs, improving power efficiency, reducing charge times, while increasing performance and productivity on the go.

Dialog operates a fabless business model and is a socially responsible employer pursuing many programs to benefit the employees, community, other stakeholders and the environment it operates in. With decades of experience and world-class innovation, we help manufacturers get to what's next. Our passion for innovation and entrepreneurial spirit ensures we remain at the forefront of power efficient semiconductor technology for the IoT, mobile, computing and storage, connected medical, and automotive markets. Dialog is headquartered near London with a global sales, R&D and marketing organization. In 2019, it had approximately $1.4 billion in revenue and is consistently one of the fastest growing European public semiconductor companies. It currently has approximately 2,300 employees worldwide. The company is listed on the Frankfurt (FWB: DLG) stock exchange (Regulated Market, Prime Standard, ISIN GB0059822006).

For more information, visit www.dialog-semiconductor.com.

Contact:
Jose Cano
Director, Investor Relations
jose.cano@diasemi.com
+44(0)1793756961

SOURCE: Dialog Semiconductor Plc via EQS Newswire

ReleaseID: 604024

Announces CRADA with National Center for Advancing Translational Sciences

WEST CHESTER, PA / ACCESSWIRE / August 31, 2020 / Virpax® Pharmaceuticals, Inc. ("Virpax"), a company specializing in developing pharmaceutical products for pain management, today announced that it has entered into a cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the continued development of Virpax's product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain.

NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form. We believe that the nanotechnology may enable and enhance the delivery of this metabolically labile peptide drug into the brain. NES100 is the first investigational product formulation delivered via the nasal route with the potential to enhance enkephalin transport to the brain. NES100 uses a preassembled device and cartridge to propel the enkephalin formulation through the nose to the brain by flowing along the olfactory nerve pathway. The Molecular Envelope Technology (MET) is designed to protect and help carry the drug to the brain with the goal of promptly suppressing pain by binding to the delta opioid receptors. NES100 has demonstrated analgesic potential in animal models without the development of opioid tolerance, withdrawal, respiratory depression, euphoria, or addiction associated with use of opioids.

Anthony P. Mack, Chairman and CEO of Virpax commented, "We are excited to announce this collaboration with NCATS and the NIH Helping to End Addiction Long-term (HEAL) initiative as we believe that it may help Virpax develop an effective and safe alternative to conventional opioids used by patients to manage acute and chronic pain. The study will be led by Dr. Jeffrey Gudin, principal investigator, and co-founder of Virpax. We believe that the NIH/NCATS collaborative agreement will enable our team to maintain momentum in both our pre-clinical and clinical development strategies."

About Virpax Pharmaceuticals

Virpax Pharmaceuticals is focused on developing branded prescription products and providing more efficient drug treatments using its proprietary cutting-edge delivery technologies designed to satisfy unmet global market needs. Virpax's pipeline consists of non-addictive products being studied to manage musculoskeletal pain, post-operative pain and moderate to severe chronic pain. While Virpax is a market leader in the development of non-addictive pain management products, Virpax is also using its patented delivery technologies to develop therapies to manage PTSD, treat post-traumatic headaches, and also a technology to help prevent viral spread, including influenza and SARS-CoV-2. For more information, please visit www.virpaxpharma.com.

Forward-Looking Statement

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar words. These statements are only predictions. Virpax cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with the timing of NES100 regulatory filings and clinical milestones and other risks and uncertainties. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Forward-looking statements reflect the Company's analysis only on their stated date, and Virpax takes no obligation to update or revise these statements except as may be required by law.

Contact

Shana Panzarella, Chief of Staff
Virpax Pharmaceuticals
484-880-4588
info@virpaxpharma.com

SOURCE: Virpax Pharmaceuticals

ReleaseID: 603825

GENEVA, SWITZERLAND / ACCESSWIRE / August 31, 2020 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound Aviptadil in advanced clinical development to treat severe COVID-19 patients, today announced their successful up-listing from OTC Pink to OTCQB, effective as of the open of trading on August 31, 2020 and a capital increase pursuant to drawdowns in the context of its Share Subscription Facility in place with the Company's main shareholder GEM Global Yield Fund LLC SCS.

As part of the Company's growth and evolution strategy, Relief successfully met all qualifications to up-list from OTC Pink to OTCQB. This will allow a broader range of investors to invest in Relief Stock. The OTCQB is operated by the OTC Markets Group, Inc. and is designed for early-stage and developing companies located both in the United States and abroad. To be eligible for quotation on the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process. Companies must also meet a minimum bid price test and be solvent. The OTCQB is recognized by the Securities and Exchange Commission as an established public market and provides current public information to investors that need to analyze, value, and trade securities. Relief intends to seek a future presence on a regulated exchange such as the NASDAQ or NYSE MKT.

In addition, Relief raised funds from the Share Subscription Facility bringing the total amount of shares outstanding to 2,534,168,581. As of August 31, 2020, Relief has an available cash balance of approximately CHF 32,000,000, which will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (Aviptadil) in COVID-19 acute respiratory distress syndrome (NCT04311697) as well as to run a phase 3 study in Europe.

"We are proud to meet the enhanced public company requirements to be an OTCQB listed company and thank all share purchasers who are contributing to this fundraising effort. The proceeds from these efforts will enable us to progress the clinical trial of Aviptadil and reach our next milestone on schedule to bring this potentially life-saving drug to patients as fast as possible," said Dr. Raghuram Selvaraju, Chairman of the Board of Directors of Relief.

About Relief
Relief focuses primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate Aviptadil, alias vasoactive intestinal peptide, is tested in two phase 2/3 trials on COVID-19 induced ARDS, plus an expanded access program (compassionate use). Aviptadil is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Aviptadil was granted FDA Fast Track Designation and emergency use IND authorization.

Relief holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a U.S. patent (US8178489 formulation for Aviptadil) for RLF-100 and proprietary manufacturing processes for its synthesis.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF.

CONTACT

RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju
Chairman of the Board
Mail: contact@relieftherapeutics.com

FOR MEDIA INQUIRES:
MC Services AG
Anne Hennecke / Brittney Sojeva
Mail: anne.hennecke@mc-services.eu
Tel.: +49 (0) 211-529-252-14

Note: GEM Global Yield Fund LLC SCS ("GGYF"), a major shareholder in RELIEF THERAPEUTICS Holding SA ("Relief"), entered into an Option Agreement with Yves Sagot, CSO of Relief, on August 31, 2017, for 66,666,667 shares of Relief. As the term of the Options had an expiration date of August 31, 2020, GGYF exercised its Options in the manner provided for in the Option Agreement and those shares have been transferred to GGYF's account.

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

ReleaseID: 604020